Kenvue Posts 3Q EPS of 22 Cents
KVUE sits 40% above its 52-week low of $14.02.
Summary
Kenvue reported third-quarter EPS of 22 cents, with adjusted EPS of 29 cents, net income of $430M and sales of $3.89B, its first quarterly print since the European Commission granted conditional approval for Kimberly-Clark's $40B acquisition on Oct. 13. The company will not be providing forward-looking guidance, citing the pending Kimberly-Clark deal, and the release gives no comparison to consensus, so the numbers alone don't tell traders whether the quarter was a beat or a miss. The stock sits at $19.60, near its 52-week high of $20.13, meaning shares are already priced close to the merger terms rather than on standalone results. With the deal cleared in Europe and Australia, the quarterly print matters less for valuation than for any signal about the deal timeline or litigation overhang. Watch for any update on the Tylenol and phenylephrine litigation, where the 2nd Circuit declined on Oct. 16 to rehear the July panel ruling.
At the time of this announcement, KVUE was trading at $19.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $37.6B. The 52-week trading range was $14.02 to $20.13. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.